Adrenocorticotropic Hormone (ACTH) (1-39)
(Synonyms: 丝拉克肽,1-39-Corticotropin (human)) 目录号 : GC12239
Adrenocorticotropic Hormone (ACTH) (1-39)是一种由垂体前叶产生的有效的黑皮质素2受体（MC2R）激动剂。
Cas No.:12279-41-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Adrenocorticotropic Hormone (ACTH) (1-39) is a potent melanocortin 2 receptor (MC2R) agonist produced by the anterior pituitary gland. As a key component of the hypothalamic-pituitary-adrenal (HPA) axis, ACTH (1-39) binds to MC2R on the surface of adrenal cells, activating the cAMP-PKA signaling pathway and thereby promoting the conversion of cholesterol to cortisol[1,2]. ACTH (1-39) is commonly used for the diagnosis of adrenal function and in the treatment and research of diseases such as multiple sclerosis relapse[3,4].
In vitro, pretreatment of neurons with ACTH (1-39) (200, 400nM) for 30min, followed by co-incubation with 25μM Quinolinic acid or Kynurenic acid for 24h, significantly attenuated Quinolinic acid-induced neuronal death, but showed no protective effect against Kynurenic acid-induced cell death[5]. Pretreatment of normal human epidermal melanocytes with ACTH (1-39) (100nM) for 24h significantly stimulated the production of cortisol and corticosterone[6]. Treatment of adrenal cells isolated from rats of different postnatal ages with ACTH (1-39) (1ng/mL) for 2h significantly enhanced corticosterone production, and this effect increased with developmental age[7].
In vivo, ACTH (1-39) (5μg), administered intra-articularly in a monosodium urate (MSU) crystal-induced recurrent arthritis model in rats (given concurrently with the second MSU injection at 72h after the first injection), significantly suppressed neutrophil infiltration, joint swelling, and arthritis scores at 96h[8]. Additionally, ACTH (1-39) (0.3mg/kg/day), delivered via continuous subcutaneous infusion using an osmotic minipump and co-administered with DEX in mice for 4 days, prevented the adrenal weight loss induced by DEX alone and completely blocked apoptosis of adrenocortical cells[9].
References:
[1] GALLO-PAYET N. 60 years of POMC: adrenal and extra-adrenal functions of ACTH[J]. Journal of molecular endocrinology, 2016, 56(4): T135-T156.
[2] HASENMAJER V, BONAVENTURA I, MINNETTI M, et al. Non-canonical effects of ACTH: insights into adrenal insufficiency[J]. Frontiers in endocrinology, 2021, 12: 701263.
[3] OELKERS W, DIEDERICHS S, BÄHR V. Diagnosis and therapy surveillance in Addison's disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone[J]. The Journal of Clinical Endocrinology & Metabolism, 1992, 75(1): 259-264.
[4] BENJAMINS J A, NEDELKOSKA L, LISAK R P. Melanocortin receptor subtypes are expressed on cells in the oligodendroglial lineage and signal ACTH protection[J]. Journal of neuroscience research, 2018, 96(3): 427-435.
[5] LISAK R P, NEDELKOSKA L, BEALMEAR B, et al. Melanocortin receptor agonist ACTH 1-39 protects rat forebrain neurons from apoptotic, excitotoxic and inflammation-related damage[J]. Experimental Neurology, 2015, 273: 161-167.
[6] SLOMINSKI A, ZBYTEK B, SZCZESNIEWSKI A, et al. CRH stimulation of corticosteroids production in melanocytes is mediated by ACTH[J]. American Journal of Physiology-Endocrinology and Metabolism, 2005, 288(4): E701-E706.
[7] LEE J J, EISENBERG P, PAPADOPOULOS V, et al. Reversible changes in adrenocorticotropin (ACTH)-induced adrenocortical steroidogenesis and expression of the peripheral-type benzodiazepine receptor during the ACTH-insensitive period in young rats[J]. Endocrinology, 2004, 145(5): 2165-2173.
[8] GETTING S J, CHRISTIAN H C, FLOWER R J, et al. Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis[J]. Arthritis & Rheumatism, 2002, 46(10): 2765-2775.
[9] THOMAS M, KERAMIDAS M, MONCHAUX E, et al. Dual hormonal regulation of endocrine tissue mass and vasculature by adrenocorticotropin in the adrenal cortex[J]. Endocrinology, 2004, 145(9): 4320-4329.
Adrenocorticotropic Hormone (ACTH) (1-39)是一种由垂体前叶产生的有效的黑皮质素2受体（MC2R）激动剂。ACTH (1-39)是下丘脑-垂体-肾上腺（HPA）轴的关键部分，通过与肾上腺细胞表面的MC2R结合，激活cAMP-PKA信号通路，进而促进胆固醇转化为皮质醇[1,2]。ACTH (1-39)通常用于肾上腺功能的诊断及多发性硬化症复发等疾病的治疗和研究[3,4]。
在体外，ACTH (1-39)（200, 400nM）预处理神经元30min，再加入25μM Quinolinic acid或Kynurenic acid处理24h，显著减轻了Quinolinic引起的神经元死亡，但对Kynurenic诱导的细胞死亡无保护作用[5]。ACTH (1-39)（100nM）预处理正常人表皮黑素细胞24h，可显著刺激皮质醇和皮质酮的生成[6]。ACTH (1-39)（1ng/mL）处理从不同日龄大鼠分离的肾上腺细胞2h，显著增强了皮质酮的生成，且该效应随发育年龄增长而增强[7]。
在体内，ACTH (1-39)（5μg）通过关节内给药处理单钠尿酸盐（MSU）晶体诱导的复发性大鼠关节炎模型（于首次注射72h后，第二次注射MSU时同时给药），能显著抑制96h时段的中性粒细胞浸润、关节肿胀和关节炎评分[8]。ACTH (1-39)（0.3mg/kg/day）通过皮下植入的微型泵持续输注与DEX共同处理小鼠4天，可防止由DEX单独处理引起的肾上腺重量减轻，并完全阻断了肾上腺皮质细胞的凋亡[9]。
| Cell experiment [1]: | |
Cell lines | Neurons (isolated from 2-3 day old rat brain) |
Preparation Method | Neuronal cultures were treated for 30min with 200nM or 400nM ACTH (1-39) before addition of 25μM kynurenic acid or 25μM quinolinic acid. After 24h, cell death was measured in neurons by uptake of trypan blue. |
Reaction Conditions | 200, 400nM; 30min |
Applications | ACTH (1-39) at either 200 or 400nM protected neurons from quinolinic acid (25μM). However, ACTH (1-39) did not protect neurons from death induced by kynurenic acid (25μM). |
| Animal experiment [2]: | |
Animal models | OF-1 male mice |
Preparation Method | Mice were treated with 1mg/kg/day DEX and 0.3mg/kg/day ACTH (1-39) via a subcutaneously implanted osmotic minipump. After 4 days, adrenal tissue was collected, surrounding adipose tissue was removed, and the mice were weighed.Cells undergoing apoptosis were detected by in situ analysis of DNA strand breaks in histological sections using a nonradioactive fragment end labeling DNA fragmentation detection kit. |
Dosage form | 0.3mg/kg/day; 4 days; Continuous infusion via a subcutaneously implanted osmotic minipump |
Applications | ACTH (1-39) treatment in mice prevented adrenal weight loss induced by DEX treatment alone and completely blocked adrenocortical cell apoptosis. |
References: | |
| Cas No. | 12279-41-3 | SDF | |
| 别名 | 丝拉克肽,1-39-Corticotropin (human) | ||
| Canonical SMILES | CC(C[C@@](/N=C(O)/[C@]1([H])CCCN1C([C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/C/N=C(O)/[C@](/N=C(O)/[C@]2([H])CCCN2C([C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@]3([H])CC | ||
| 分子式 | C207H308N56O58S | 分子量 | 4541.1 |
| 溶解度 | Soluble to 1 mg/ml in Water | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 220.2 μL | 1.1011 mL | 2.2021 mL |
| 5 mM | 44 μL | 220.2 μL | 440.4 μL |
| 10 mM | 22 μL | 110.1 μL | 220.2 μL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet